Liposomal amphotericin B (L-AMB) is a lipid formulation of amphotericin B. As with the other lipid formulations, the major goal of developing L-AMB has been to attain a compound with lower toxicity and with at least similar efficacy compared to the parent compound, amphotericin B deoxycholate.
L-AMB is composed of amphotericin B complexed with hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, and cholesterol. Unlike the other lipid formulations of amphotericin B, it is a true liposome composed of unilamellar lipid vesicles. L-AMB is being manufactured by Nexstar Pharmaceuticals (San Dimas, CA, USA). Its trade name is Ambisome™.
Compared to the other lipid formulations of amphotericin B, L-AMB reaches higher concentrations in plasma and remains in the circulation longer. Similar to the other lipid formulations, L-AMB concentrates in reticuloendothelial system. However, its uptake to the reticuloendothelial system cells is slower. This feature is presumably due to the smaller size, higher transition (melting) temperature and more rigid bilayer of the liposome. This finally provides a persistent pool of L-AMB in plasma and a sustained delivery to the site of infection. L-AMB attains high concentrations in brain tissue.
However it is recommended to check with your pharmacist/doc., hope this helps.
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Updated 12 Nov 2009 • 1 answer
Updated 7 Mar 2011 • 1 answer
Updated 18 Apr 2011 • 1 answer
Updated 25 Mar 2015 • 1 answer
Updated 4 Sep 2015 • 1 answer